Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed this ...

EVERSANA has signed an agreement with Oracle Argus Cloud to add to the features of its pharmacovigilance platform, which ...

Artificial intelligence (AI) is an increasingly valuable tool in our perpetual quest for the miracles that science regularly ...

At LSX 2024 in Boston last month, editor-in-chief Jonah Comstock spoke with James Graham, CEO and founder of Recce Pharma, an ...

For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments. However, ...

Embarking on the journey of a medical start-up is like navigating a complex labyrinth, where the final prize is the coveted ...

In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

As Frontiers Health 2024 approaches, taking place in Berlin 17th and 18th October, pharmaphorum sat down with one of its ...